Unresectable hepatocellular carcinoma
Conditions
Interventions
Prospective research Section:None
Sponsors
Wuxi people’s Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Retrospective study section: (1) Patients diagnosed with HCC according to the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2024 Edition); (2) BCLC stage A/B/C, and surgically or oncologically unresectable; (3) complete clinical, imaging, and liver biopsy pathological data; having received combination therapy (intra-vascular intervention + targeted therapy + immunotherapy); (4) ECOG performance status score = 3 months, with complete follow-up data. 2. Prospective study section: (1) Patients diagnosed with HCC according to the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2024 Edition); (2) BCLC stage A/B/C, and surgically or oncologically unresectable; (3) complete clinical, imaging, and liver biopsy pathological data; (4) planned to receive combination therapy (intra-vascular intervention combined with targeted and immunotherapy); (5) ECOG performance status score <= 2; (6) voluntarily participating in this study and having signed an informed consent form; (7) able to cooperate with the completion of liver biopsy and the collection of hepatic artery/hepatic vein blood samples.
Exclusion criteria
Exclusion criteria: 1. Retrospective study section: (1) Previous treatment with local or systemic therapy; (2) pathological findings indicating mixed hepatocellular carcinoma–cholangiocarcinoma; (3) concurrent other malignancies; (4) inability to obtain imaging data or pathological tissue samples. 2. Prospective study section: (1) Previous treatment with local or systemic therapy; (2) pathological findings indicating mixed hepatocellular carcinoma-cholangiocarcinoma; (3) concurrent other malignancies; (4) contraindications to liver biopsy or related tests; (5) inability to comply with follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate (ORR);Overal survival (OS);Progression free survival(PFS);Molecular characteristics in patients with different prognostic stratifications; | — |
Secondary
| Measure | Time frame |
|---|---|
| Tumor shrinkage rate;Adverse events during liver biopsy and specimen collection; | — |
Countries
China
Contacts
Public ContactWang Weidong
Wuxi people’s Hospital
Outcome results
None listed